# A Double-blind, Double-dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg Versus Rofecoxib 50 mg in Treating the Symptoms of Ankle Sprain

> **NCT00657449** · PHASE4 · TERMINATED · sponsor: **Pfizer** · enrollment: 45 (actual)

## Conditions studied

- Acute Pain

## Interventions

- **DRUG:** valdecoxib
- **DRUG:** rofecoxib

## Key facts

- **NCT ID:** NCT00657449
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-06-04
- **Primary completion:** 2004-10-01
- **Final completion:** 2004-10-05
- **Target enrollment:** 45 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2018-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00657449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00657449, "A Double-blind, Double-dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg Versus Rofecoxib 50 mg in Treating the Symptoms of Ankle Sprain". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00657449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*